Immunotherapeutic approaches to sarcoma | JoVE Visualize

Area of Science:

Oncology
Immunology
Cancer Therapy

Background:

Advanced sarcomas have limited treatment options with current cytotoxic chemotherapy, showing modest efficacy and significant toxicity.
Despite imatinib and pazopanib approvals, progress in advanced sarcoma treatment has been slow, necessitating novel therapeutic strategies.

Purpose of the Study:

To evaluate the potential of immunotherapy, specifically checkpoint inhibitors, as a novel therapeutic approach for advanced sarcomas.
To explore emerging immunotherapy strategies like vaccines, adoptive T cell therapy, and chimeric antigen receptor (CAR)-engineered T cells in sarcoma treatment.

Main Methods:

Review of current literature on advanced sarcoma therapies, including chemotherapy and emerging immunotherapies.
Analysis of preclinical data and early clinical trial results for immunotherapy in various solid tumors and specific sarcoma subtypes.
Focus on checkpoint inhibitors targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) based on their success in other cancers.

Main Results:

Immunotherapy, particularly PD-1/PD-L1 inhibitors, has shown significant clinical benefit and durable responses in multiple solid tumors, suggesting potential in sarcoma.
Preclinical data and small studies indicate promise for vaccines and adoptive T cell therapy in specific sarcoma subtypes like synovial sarcoma.
Checkpoint inhibitors targeting PD-1/PD-L1 demonstrate unprecedented clinical activity and an excellent safety profile, generating enthusiasm for sarcoma treatment.

Conclusions:

Immunotherapy, especially checkpoint inhibitors, holds significant promise for treating advanced sarcomas, offering a potential new avenue for durable responses.
Further research, including ongoing phase II studies, is crucial to establish the efficacy of immunotherapy in sarcoma.
Future strategies should prioritize patient selection and combination therapies (e.g., with targeted therapy, chemotherapy, or radiation) for optimal treatment outcomes in advanced sarcomas.